Specialty Pharmacy Access: When Refills Decided Who Got the Next Patient

Specialty pharmacy limited distribution network access has two gates: manufacturer permission to dispense the drug and the patient’s reimbursable pharmacy network. Accreditation sits alongside both. A pharmacy can meet the accreditation requirements and still lack access to the product, or have the product and fall outside the patient’s network.

Novartis’s Exjade admissions show what happened inside one network: pharmacies competed for new patients on a refill score that counted a doctor’s instruction to stop treatment against them. Patient support with a sales scoreboard.

Specialty Pharmacy Access Starts With Separate Agreements

The manufacturer agreement governs access to its product. The payer or pharmacy benefit manager agreement governs the pharmacy’s participation, reimbursement and service terms for the patient’s benefit. The useful comparison starts with the drug, pharmacy, patient coverage and terms in force when the prescription arrived.

Manufacturer Permission Is Product Specific

Limited distribution means that a drug is available through a selected network of specialty pharmacies. In its annual report for 2017, Diplomat Pharmacy described working with manufacturers before a drug’s launch to obtain access. It said those relationships could lead to exclusive rights or a place on a small panel of authorized pharmacies.

The same filing explains what a pharmacy offered the manufacturer: patient monitoring, adherence support and clinical information. Diplomat reported receiving fees from certain manufacturers for clinical data. Product access and the services sold alongside it belonged to the same commercial relationship. We compare those service promises with patient contact, dispensing and data records to see what the pharmacy actually did.

The filing also described REMS, the FDA’s risk evaluation and mitigation strategies for certain drugs. These programs could require specialized training, designated dispensing locations and patient monitoring.

Accreditation Assesses Capability

Accreditation assesses a pharmacy against an accreditor’s standards. State licensure, payer enrollment, manufacturer access and network acceptance each have their own documents.

Diplomat’s filing listed specialty and infusion pharmacy accreditation from the Accreditation Commission for Healthcare, covering matters such as therapy monitoring and patient counseling. It separately described URAC specialty pharmacy accreditation, including documentation review and an on-site survey. For an access question, we match the credential to the pharmacy and premises, then to the manufacturer and payer requirements.

The Patient’s Benefit Controls Reimbursement

The payer’s network agreement addresses participation, rates, adjustments and services. Preferred status and prior authorization add further questions about how the patient’s prescription will be covered.

The CalPERS prescription benefit booklet for 2026 illustrates how specific those terms can be. It describes preferred-specialty sequencing, prior authorization and exceptions, with a maximum 30-day specialty supply. Its ordinary 90-day benefit can use home delivery or a participating retail pharmacy.

The pharmacy also has work to do between receiving a prescription and obtaining payment. Diplomat described prior-authorization specialists coordinating with prescribers, assembling patient information and supporting documents, and pursuing formulary exceptions. The request, the clinical support and the payer’s response show what happened to that particular prescription.

Delivery Has Its Own Records

A specialty prescription can involve shipment to a patient’s home or a physician’s office. Diplomat described buying drugs from manufacturers and wholesalers, then filling, labeling, packaging and delivering them through contract couriers. Its reported distribution capabilities included temperature controls, package tracking and delivery signatures.

We connect the shipment to the prescription and payment. The receiving patient or treatment site matters alongside the pharmacy named in the network agreement.

What the Access Records Show

We connect the prescription to the access decision, dispensing and payment across records held by different participants. Claims and payment records show which prescriptions the government paid for.

Patient support produces another useful set of records. Diplomat described systems that tracked clinical interventions, prescription status, adherence, discontinuation and payer information. Its filing also described refill contacts to verify the dose and shipping address, discuss side effects and confirm how the patient was taking the medicine.

For an insider, the connection may already be familiar: the patient stopped treatment, the system recorded why, and the pharmacy’s performance report treated the stop differently. The Exjade cases show exactly why that comparison matters.

Exjade Referrals Followed the Refill Score

As part of its November 2015 settlement, Novartis admitted distributing Exjade through a closed network of three specialty pharmacies: BioScrip, Accredo and US Bioservices. Within that network, refill performance could bring a pharmacy more new patients.

Doctors sent registration forms and prescriptions to LASH Group, the vendor administering the network for Novartis. Some prescriptions went to a particular pharmacy because an insurer or physician required it. Novartis controlled the allocation of the remaining, undesignated patients. This is the point where the access story becomes a referral story: all three pharmacies had permission to dispense, while the manufacturer controlled a flow of new business among them.

BioScrip explained the value of that flow in its own settlement admissions:

New patients were the incentive. Each referral could bring the pharmacy the initial prescription and subsequent refills, along with the associated fees and rebates.

A Doctor’s Stop Order Still Counted Against the Score

The Exjade adherence score measured how long patients kept ordering refills. Novartis admitted excluding deceased patients from that calculation while leaving in patients whose physicians had directed them to stop therapy or who stopped because of side effects.

BioScrip separately admitted that side effects and doctors’ instructions were among the most common reasons its patients stopped ordering refills. It collected those reasons under its contract and sent the information to Novartis monthly. The clinical explanation was already in the program’s health care records.

We see a sales contest built into a patient-support program. The pharmacy could record that a doctor wanted treatment stopped and still lose ground in the competition for the next patient.

Novartis admitted that, in the first half of 2009, BioScrip received 60% of undesignated patients because it had the highest adherence score. Accredo and US Bioservices each received 20%. The allocation applied to the patients insurers and physicians had left undesignated.

The Written Contract Left Out the Allocation Rule

Novartis admitted that neither the original pharmacy agreements nor their amendments specified how the volume of undesignated patients would be determined. The scorecards and allocation records supplied a commercial term the contracts left out.

BioScrip’s admissions show the pressure behind that term. Novartis told the pharmacy that low refill performance could cost it new patient referrals and potentially its place in the network. BioScrip responded by assigning staff to encourage refills and restart patients who had stopped ordering the drug.

The incentive also appeared in the price paid for each shipment. BioScrip admitted that its rebate increased from $13 to $20 in January 2008 in recognition of its performance and, as BioScrip understood it, to encourage its team’s continued efforts. Patient allocation and shipment payments both rewarded the refill effort.

Nurse Calls Belonged Beside the Scorecards

The call instructions show what the pharmacy did to improve its score. Novartis admitted that Accredo supplied a call template emphasizing the importance of continuing Exjade and the consequences of untreated iron overload. The template asked about side effects but did not specifically direct nurses to discuss kidney or liver impairment.

Novartis also admitted that, after a boxed warning was added in January 2010, it trained the pharmacies on the warning but did not ask them to revise their scripts to require discussion of kidney impairment, liver impairment or gastrointestinal bleeding. The manufacturer knew the warning had changed while the refill program continued.

The performance-based allocation ended in April 2012, according to Novartis’s admissions. Accredo stopped assigning nurses to make those therapy calls that month. The change connects the referral incentive with the staffing devoted to it.

The Pharmacy Cases Followed the Same Patient Flow

The Exjade healthcare fraud settlements addressed referrals tied to prescriptions billed to Medicare and Medicaid. BioScrip agreed to an approximately $15 million civil settlement in January 2014. Accredo’s civil settlement announced in May 2015 was $60 million. They were separate pharmacy settlements over participation in the Exjade arrangement.

Novartis separately agreed to a $370 million civil settlement in November 2015 over alleged pharmacy kickbacks involving Exjade and Myfortic. The government alleged that its Exjade incentives caused pharmacies to submit false claims to Medicare and Medicaid.

US Bioservices agreed to a $13.4 million settlement announced in August 2017. The government alleged that the company accepted promises of additional patients in exchange for higher refill performance and submitted thousands of Exjade prescriptions to Medicare and Medicaid. Its admissions described the same scorecard and allocation mechanism, along with nurse training intended to improve its adherence score.

The US Bioservices release also identifies a practical difference: its nurses did not use written scripts for their patient calls. Training records and the work staff actually performed therefore belong beside any written protocol. A review that stops at the service contract misses the conduct the referral incentive was intended to produce.

Connecting Access Decisions to a Whistleblower Case

A specialty pharmacy referral inquiry follows who controlled the patient flow, what the pharmacy did to receive it and which prescriptions the government paid for. The access agreement supplies the starting relationship. Scorecards, allocation instructions, patient-stop reasons, staff training and claims show what that relationship produced.

An employee in contracting may know what the agreement promised. Someone handling referrals may know how patients were assigned. A pharmacist or nurse may know why treatment stopped and what staff were told to say. We connect those accounts to the dispensing and payment records, including the dates when the rules or practices changed. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

When You Know Why the Next Patient Was Sent Elsewhere

If you know how a specialty pharmacy’s contracts, performance scores or patient calls affected its referrals, speak with our whistleblower experts about that connection. We work beside you to build your strongest specialty pharmacy whistleblower case around the decisions you saw and the government-paid prescriptions they produced. We bring in specialty pharmacy whistleblower lawyers who understand referral arrangements and we stay with you through the whole journey.